Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

10.07 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 10.07
Bid (Size) 10.18 (100)
Ask (Size) 11.83 (300)
Prev. Close 10.07
Today's Range 10.07 - 10.07
52wk Range 4.930 - 14.27
Shares Outstanding 33,197,018
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
From Entrada Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+0.2%
+0.2%
1 Month
-0.1%
-0.1%
3 Month
+44.9%
+44.9%
6 Month
+90.0%
+90.0%
1 Year
-28.0%
-28.0%

More News

Read More
News headline image
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock ↗
Via Benzinga
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
Via The Motley Fool
News headline image
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada (TRDA) Q2 Revenue Drops 98% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Entrada Therapeutics Inc (NASDAQ:TRDA) Reports Q2 2025 Earnings Miss, Shares Drop in Pre-Market Trading ↗
Via Chartmill
Topics Earnings
News headline image
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports First Quarter 2025 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy ↗
Via Benzinga
News headline image
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Entrada Therapeutics, Inc. - Common Stock publicly traded?
Yes, Entrada Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Entrada Therapeutics, Inc. - Common Stock trade on?
Entrada Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Entrada Therapeutics, Inc. - Common Stock?
The ticker symbol for Entrada Therapeutics, Inc. - Common Stock is TRDA on the Nasdaq Stock Market
What is the current price of Entrada Therapeutics, Inc. - Common Stock?
The current price of Entrada Therapeutics, Inc. - Common Stock is 10.07
When was Entrada Therapeutics, Inc. - Common Stock last traded?
The last trade of Entrada Therapeutics, Inc. - Common Stock was at 02/05/26 04:00 PM ET
What is the market capitalization of Entrada Therapeutics, Inc. - Common Stock?
The market capitalization of Entrada Therapeutics, Inc. - Common Stock is 334.29M
How many shares of Entrada Therapeutics, Inc. - Common Stock are outstanding?
Entrada Therapeutics, Inc. - Common Stock has 334M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.